Sihegene

Sihegene is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative gene therapies. The company focuses on utilizing Adeno-associated virus (AAV) vector technology to treat rare genetic disorders, including hemophilia and metabolic diseases. Its lead programs, such as SHG002 for Hemophilia B, have entered clinical trials, demonstrating the company's capability in moving from discovery to human testing. Sihegene aims to provide one-time curative treatments for patients with high unmet medical needs through its proprietary vector engineering and manufacturing platforms. The company is supported by prominent venture capital firms and maintains a robust R&D infrastructure.